Biogen BIIB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.5%-0.1pp | 75.7%-0.4pp | 75.2%-0.3pp | 75.4%-0.1pp | 75.6%+0.5pp | |
| Net margin | 14.3%-0.8pp | 13.6%-3.3pp | 16%-0.8pp | 15.3%+3.3pp | 15.1%+3.0pp | |
| EBITDA margin | 27%+0.1pp | 26.2%-2.4pp | 28.5%+0.1pp | 27.4%+5.8pp | 26.9%+5.9pp | |
| Free cash flow margin | 24.4%-0.4pp | 20.7%-7.4pp | 22.9%+2.1pp | 19.8%+3.1pp | 24.8%+9.9pp | |
| Returns | ||||||
| Return on equity | 8%-1.2pp | 7.7%-2.7pp | 9.3%-1.2pp | 9.1%+1.5pp | 9.2%+1.1pp | |
| Return on assets | 4.9%-0.5pp | 4.7%-1.3pp | 5.6%-0.1pp | 5.6%+1.1pp | 5.4%+0.9pp | |
| Return on invested capital | 7.8%-0.4pp | 7%-1.5pp | 8.8%-0.3pp | 8%+1.2pp | 8.1%+1.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 19×-3.6× | 20.1×-6.2× | 19.4×-11.8× | 18.8×-8.0× | 22.6×-12.6× | |
| Liquidity | ||||||
| Current ratio | 3.1×+1.6× | 2.7×+1.3× | 2.7×+1.5× | 2.5×+0.2× | 1.4×-0.7× | |
| Quick ratio | 3×+1.6× | 2.6×+1.3× | 2.7×+1.4× | 2.5×+0.2× | 1.4×-0.6× | |
| Cash ratio | 1.1×+0.6× | 0.9×+0.5× | 1.2×+0.9× | 0.9×+0.3× | 0.5×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.1× | 0.4×0.0× | 0.4×+0.1× | 0.4×0.0× | 0.3×-0.2× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | 0.2×0.0× | 0.2×-0.1× | |
| Net debt / EBITDA | 1.2×+0.3× | 1.4×-0.2× | 1×-0.2× | 1.4×-0.9× | 0.9×-1.9× | |
| Per Share | ||||||
| Book value per share | $125.69+8.5% | $124.11+8.3% | $123.78+10.5% | $120.20+10.4% | $115.82+11.1% | |
| Valuation | ||||||
| Market capitalization | $26.91B+34.3% | $25.82B+15.9% | $20.54B-27.3% | $18.51B-45.2% | $20.03B-36.1% | |
| Enterprise value | $30.08B+34.9% | $29.47B+10.7% | $23.27B-26.0% | $22.34B-42.0% | $22.3B-39.7% | |
| Price / earnings | 18.9×+5.4× | 19.2×+5.6× | 12.8×-4.7× | 12.1×-17.0× | 13.5×-13.3× | |
| Price / sales | 2.7×+0.7× | 2.6×+0.3× | 2×-0.9× | 1.9×-1.6× | 2×-1.2× | |
| Price / book | 1.4×+0.3× | 1.4×+0.1× | 1.1×-0.6× | 1×-1.1× | 1.2×-0.9× | |
| EV / EBITDA | 11.2×+2.8× | 11.4×+1.8× | 8.1×-3.4× | 8.2×-10.3× | 8.4×-9.7× | |
| EV / sales | 3×+0.8× | 3×+0.2× | 2.3×-1.0× | 2.2×-1.7× | 2.3×-1.6× | |
| Free cash flow yield | 9%-3.2pp | 7.9%-4.3pp | 11.2%+4.1pp | 10.7%+5.9pp | 12.2%+7.6pp | |
| Earnings yield | 5.3%-2.1pp | 5.2%-2.1pp | 7.8%+2.1pp | 8.3%+4.8pp | 7.4%+3.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Biogen's profit margins?
- Biogen (BIIB) runs a 75.5% gross margin and a 22.9% operating margin, with a 14.3% net margin.
- Where do Biogen's ratios come from?
- Every ratio is computed from Biogen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
